Cipla Kenya Ltd C/O Imperial Manage Pharmaceutical Import Profile — Kenya (DGFT 2022–2026)

Name: Cipla Kenya Ltd C/O Imperial Manage Pharmaceutical Import Records from India — 3 Products, $550.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cipla Kenya Ltd C/O Imperial Manage — Pharmaceutical Importer Profile (2026) | 3 Products, $550.0K Trade | TransData Nexus

Cipla Kenya Ltd C/O Imperial Manage

Pharmaceutical Importer · Kenya · Gastrointestinal Focus · $550.0K Total Trade · DGFT Verified

Cipla Kenya Ltd C/O Imperial Manage is a pharmaceutical importer based in Kenya with a total trade value of $550.0K across 3 products in 3 therapeutic categories. Based on 11 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cipla Kenya Ltd C/O Imperial Manage sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Cipla Kenya Ltd C/O Imperial Manage — Import Portfolio & Supplier Network

Cipla Kenya Ltd C/O Imperial Manage import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cipla Kenya Ltd C/O Imperial Manage?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$348.5K	47	100.0%

Cipla Kenya Ltd C/O Imperial Manage sources from 1 verified Indian supplier across 30 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Cipla Kenya Ltd C/O Imperial Manage Import?

Formulation	Value	Ships
Esclam kit(amoxicillin 1000MG tablets,clarithromycin 500MG & esomeprazole 20MG dr tablets)[ps:7x1x6x10100pac=424200	$100.0K	2
Esomac 20 MG tablets (esomeprazole 20MG)(Pack size:2x14x22650 Pack=634200 nos)	$50.0K	1
Esomac 40 MG tablets (esomeprazole 40MG)[pac size:1x14x27270 pac=381780	$50.0K	1
Asthalin 100mcg inhaler (salbutamol sulphate) (1 x 200 md)	$42.5K	3
Cefasyn 500MG TAB (cefuroxime axetil) (24000 packs x 1x10s=240000 nos)	$29.3K	1
Cefasyn 500MG TAB (cefuroxime axetil) (23800 packs x 1x10s=238000 nos)	$29.0K	3
Esomac 20 MG tablets (esomeprazole20mg) (27180 packs x 2x14's = 761040 nos)	$25.4K	3
Diracip m ds TAB (diloxanide furoate 500MG+metronidazole 400MG) (25720 packs x 1x 15s = 385800 nos)	$12.9K	1
Foralin 100 inhaler (cfc free) (with dose indicator) (formoterol fumarate 6mcg+budesonide 100mcg)(pac size:1x120 md)	$5.3K	1
Foralin 400 inhaler (cfc free) (with dose indicator) (formoterol fumarate 6mcg+budesonide 400mcg ) (1 x 120 md)	$4.0K	1
We intend to claim benefit under	$0	4
As amended from time to time including realisation/repatriation of foreign exchange to or form	$0	3
I/we undertake to abide by the provisions of foreign exchange management act,1999	$0	3
Applied online for lut-arn-ad2703230455166 valid till 31.03.2024	$0	1
Buliding no b-1 gala no.7a&8,9,10&11 survey no.121/10a,121/10b & 69 village vadape bhiwandi	$0	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Esomeprazole	Gastrointestinal	$350.0K	7	0.1%	15
2	Clarithromycin	Antibiotics	$100.0K	2	0.1%	5
3	Kit	Medical Devices & Diagnostics	$100.0K	2	0.0%	7

Cipla Kenya Ltd C/O Imperial Manage imports 3 pharmaceutical products across 3 categories into Kenya totaling $550.0K.

Cipla Kenya Ltd C/O Imperial Manage — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cipla Kenya Ltd, operating under the management of Imperial Managed Solutions East Africa Ltd, is a pharmaceutical importer and buyer based in Kenya. The company specializes in the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, sourced primarily from India. This strategic sourcing aligns with Kenya's significant reliance on imported medicines, with imports constituting approximately 80% of the pharmaceutical products used locally as of February 2024. (the-star.co.ke)

Imperial Managed Solutions East Africa Ltd, the managing entity, is located in Nairobi, Kenya, and serves as a logistics and supply chain intermediary, facilitating the importation and distribution processes for Cipla Kenya Ltd. The collaboration between Cipla Kenya Ltd and Imperial Managed Solutions East Africa Ltd underscores a strategic partnership aimed at ensuring a steady supply of essential pharmaceutical products to meet the healthcare needs of the Kenyan population.

2Distribution Network

Cipla Kenya Ltd, through its management by Imperial Managed Solutions East Africa Ltd, operates a distribution network that encompasses key regions within Kenya. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are designed to ensure efficient delivery of pharmaceutical products across the country. This distribution network is crucial in a market where imported medicines constitute a significant portion of the pharmaceutical products used locally. (the-star.co.ke)

The distribution strategy likely includes partnerships with local wholesalers, healthcare institutions, and pharmacies to ensure that imported products are accessible to various segments of the Kenyan healthcare system. By leveraging these partnerships, Cipla Kenya Ltd aims to enhance the availability and accessibility of essential medicines throughout Kenya.

3Industry Role

Cipla Kenya Ltd, under the management of Imperial Managed Solutions East Africa Ltd, functions as a pharmaceutical importer and distributor within Kenya's healthcare supply chain. The company plays a pivotal role in sourcing and supplying finished pharmaceutical formulations from India, addressing the substantial demand for imported medicines in the Kenyan market. This role is particularly significant given the challenges faced by local manufacturers in meeting the domestic demand for pharmaceutical products. (the-star.co.ke)

By importing a diverse range of pharmaceutical products, Cipla Kenya Ltd contributes to the diversification of the local pharmaceutical market, offering healthcare providers and patients access to a variety of treatment options. This involvement is essential in a market where the majority of pharmaceutical products are imported, highlighting the company's integral position in ensuring the availability of essential medicines in Kenya.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cipla Kenya Ltd C/O Imperial Manage

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cipla Kenya Ltd's sourcing strategy is characterized by a high degree of concentration, with a total import value of $550,000 USD from India over 11 shipments, primarily sourced from a single supplier, Cipla Limited. This single-source dependency indicates a strategic choice to maintain a consistent supply of pharmaceutical products from a reputable manufacturer. Cipla Limited, headquartered in Mumbai, India, is a leading global pharmaceutical company known for its extensive portfolio and commitment to quality.

The stability of this relationship is evidenced by the consistent importation of 47 shipments from Cipla Limited, suggesting a reliable and ongoing partnership. However, this concentration also presents potential risks, such as supply chain disruptions or changes in regulatory policies affecting imports from India. To mitigate these risks, Cipla Kenya Ltd may consider diversifying its supplier base or establishing contingency plans to ensure a continuous supply of essential medicines to the Kenyan market.

2Supply Chain Resilience

Cipla Kenya Ltd's supply chain resilience is closely tied to its sourcing strategy from Cipla Limited in India. The company's reliance on a single supplier streamlines procurement processes but also exposes it to potential risks associated with supply chain disruptions, such as logistical challenges or regulatory changes affecting imports from India. To enhance resilience, Cipla Kenya Ltd may explore establishing relationships with additional suppliers or developing contingency plans to address potential disruptions.

Importing Pharmaceuticals into Kenya — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Kenya

1Regulatory Authority & Framework

In Kenya, the regulation of pharmaceutical products is overseen by the Pharmacy and Poisons Board (PPB), which operates under the Ministry of Health. The PPB is responsible for ensuring that all pharmaceutical products imported, manufactured, and distributed within Kenya meet the required standards of quality, safety, and efficacy. This includes the registration of drugs, issuance of import permits, and monitoring of compliance with Good Manufacturing Practices (GMP).

Key legislation governing pharmaceutical imports includes the Pharmacy and Poisons Act (Cap. 244) and the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules. These regulations outline the procedures for drug registration, importation, and distribution, ensuring that all pharmaceutical products in the Kenyan market are duly registered and approved by the PPB. The Act and associated rules provide a comprehensive framework for the regulation of health products and technologies, including medicinal products, medical devices, and diagnostics.

2Import Licensing & GMP

Importers of pharmaceutical products into Kenya are required to obtain an import license from the Pharmacy and Poisons Board (PPB) for each consignment. This process involves submitting an application that includes details of the product, its intended use, and the manufacturing site. Additionally, importers must ensure that the products comply with Good Manufacturing Practices (GMP) as recognized by the PPB. GMP certification from reputable authorities, such as the World Health Organization (WHO) or the European Union (EU), is typically recognized by the PPB, facilitating the importation process. (infotradekenya.go.ke)

Cipla Kenya Ltd C/O Imperial Manage — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cipla Kenya Ltd's product strategy focuses on importing pharmaceutical formulations across three therapeutic categories: gastrointestinal, antibiotics, and medical devices & diagnostics. The gastrointestinal category accounts for 63.6% of imports, antibiotics 18

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Cipla Kenya Ltd C/O Imperial Manage

What products does Cipla Kenya Ltd C/O Imperial Manage import from India?

Cipla Kenya Ltd C/O Imperial Manage imports 3 pharmaceutical products across 3 categories. Top imports: Esomeprazole ($350.0K), Clarithromycin ($100.0K), Kit ($100.0K).

Who supplies pharmaceuticals to Cipla Kenya Ltd C/O Imperial Manage from India?

Cipla Kenya Ltd C/O Imperial Manage sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $348.5K).

What is Cipla Kenya Ltd C/O Imperial Manage's total pharmaceutical import value?

Cipla Kenya Ltd C/O Imperial Manage's total pharmaceutical import value from India is $550.0K, based on 11 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cipla Kenya Ltd C/O Imperial Manage focus on?

Cipla Kenya Ltd C/O Imperial Manage imports across 3 categories. The largest: Gastrointestinal (63.6%), Antibiotics (18.2%), Medical Devices & Diagnostics (18.2%).

Get Full Cipla Kenya Ltd C/O Imperial Manage Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.